Materiały źródłowe

• #1 Treatments for Alzheimer’s & Dementia | Alzheimer’s Association

  https://www.alz.org/alzheimers-dementia/treatments

  There’s no cure for Alzheimers, but there are treatments that may change disease progression, and drug and non-drug options that may help treat symptoms. […] Donanemab (Kisunla) has received traditional approval from the FDA for the treatment of early Alzheimer’s disease. […] Lecanemab (Leqembi) has received traditional approval from the FDA for the treatment of early Alzheimer’s disease. […] The first FDA-approved therapy to address the underlying biology of Alzheimers disease has been discontinued. […] CMS has released more details about its plan to cover FDA-approved drugs, including lecanemab, for Alzheimer’s disease. […] Although current medications cannot cure Alzheimers, one treatment addresses the underlying biology. Other medications may help lessen symptoms.

• #2 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  Several prescription drugs are approved by the U.S. Food and Drug Administration (FDA) for Alzheimers disease to help either manage the symptoms of or to treat the disease. Most FDA-approved drugs work best for people in the early or middle stages of Alzheimers. There are currently no known interventions that will cure Alzheimers. […] Treating the symptoms of Alzheimers can help provide people with comfort, dignity, and independence for a longer period of time and also assist their caregivers. Galantamine, benzgalantamine, rivastigmine, and donepezil are cholinesterase inhibitors that are prescribed for mild to moderate Alzheimers symptoms. These drugs may help reduce or control some cognitive and behavioral symptoms. […] Lecanemab and donanemab are FDA-approved immunotherapy drugs for the treatment of early Alzheimers. These drugs target the protein beta-amyloid to help reduce amyloid plaques, one of the hallmark brain changes in Alzheimers.

• #3 Treatment and support of Alzheimer’s disease | Alzheimer’s Society

  https://www.alzheimers.org.uk/about-dementia/types-dementia/treatment-support-alzheimers-disease

  There is no cure for Alzheimers disease yet. However, with the right care and support, it is possible for someone with Alzheimer’s to live as well as possible for as long as possible. […] Support can include useful information, support from family, friends and the wider community as well as treating symptoms with medicines and other therapies. […] Taking a medicine to help with memory and thinking can help many people live well with Alzheimers disease. These cannot stop the physical disease from progressing in the brain, but in some cases they may delay the symptoms getting worse. […] A wide range of medicines may be prescribed at different times for a person with Alzheimers. […] If a person is in distress, health professionals will generally recommend trying approaches that dont involve medication first before prescribing something, unless a persons symptoms are very severe and there is a risk of harm to them or others.

• #4 Alzheimer’s disease – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453

  Other medicines have been approved by the Food and Drug Administration, also called FDA, to slow declines in thinking and functioning caused by Alzheimer’s disease. The medicines prevent amyloid plaques in the brain from clumping. They’re prescribed for people with mild Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease. […] Lecanemab-irmb (Leqembi). This medicine is given as an IV infusion every two weeks. Side effects may include infusion-related reactions such as fever, flu-like symptoms, nausea, vomiting, dizziness, changes in heart rate and trouble breathing. […] Donanemab-azbt (Kisunla). This medicine is given as an IV infusion every four weeks. Side effects may include flu-like symptoms, nausea, vomiting, headache, trouble breathing and changes in blood pressure.

• #5 Treatments | Stanford Health Care

  https://stanfordhealthcare.org/medical-conditions/brain-and-nerves/alzheimers-disease/treatments.html

  The Stanford Health Care Center for Memory Disorders is encouraged that there is another new treatment option for certain patients with Alzheimers disease. Our neurologists are preparing to begin prescribing Donanemab. […] Currently, there is no cure for Alzheimer’s disease and no treatment available to reverse the deterioration of Alzheimer’s disease. New research findings give reason for hope, and several drugs are being studied in clinical trials to determine if they can slow the progress of the disease or improve memory for a time. […] The FDA has approved two therapies that may help slow the progression of Alzheimers disease, Lecanemab and Donanemab. A third, aducanumab, is no longer on the market.

• #6 What To Know About New Alzheimer’s Disease Treatments – Neurology

  https://healthmatters.nyp.org/what-to-know-about-new-alzheimers-disease-treatments/

  Lecanemab is a monoclonal antibody that binds amyloid and was designed to remove amyloid from the brain. It has long been suggested that removing the protein might slow the progression of Alzheimers disease. Donanemab is another drug of the same broad class. Like lecanemab, it removes beta amyloid and slows disease progression. […] Do they slow them down? Yes, they do slow Alzheimers disease as measured in a variety of ways, including by reducing amyloid levels. And these are the first medications clinically proven to do so. […] Results of the clinical trial, which were published in the New England Journal of Medicine, showed that it slowed decline for people with early Alzheimers disease by about 27% to 37%, depending on the clinical test measure. […] In donanemabs phase 3 clinical trial, treatment with the drug was associated with dramatic amyloid removal from the brain, as well as slowing of progression of the disease for patients in the early stages of Alzheimers.

• #7 Alzheimer’s Disease Treatments

  https://www.aarp.org/health/conditions-treatments/alzheimers-treatments/

  Two drugs have full FDA approval to treat people with early stage Alzheimers. Both drugs target one of the abnormal proteins that build up in the brains of Alzheimers patients, and both approvals came with caution. The drugs are named Leqembi (lecanemab) and Kisunla (donamemab). […] Leqembi and Kisunla are monoclonal antibodies that help remove amyloid plaques that build up in the brains of people with Alzheimers disease. […] In a phase 3 study comparing the drug with placebos, Leqembis makers, Eisai and Biogen, showed that Leqembi reduced the level of amyloid plaques while slowing the rate of cognitive decline by 27 percent over 18 months in patients in the early stages of Alzheimers. […] It doesnt stop the disease, and it doesnt make people get better, but it slows down the rate where people get worse, says Ronald Petersen, M.D., director of the Mayo Clinic Alzheimers Disease Research Center.

• #8 Navigating Treatment Options | alz.org

  https://www.alz.org/alzheimers-dementia/treatments/navigating-treatment-options

  Donanemab (Kisunla) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every four weeks. It has received traditional approval from the FDA to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain. The positive data from the clinical studies showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (either mild cognitive impairment or mild dementia). […] Lecanemab (Leqembi) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every two weeks. It has received traditional approval from the FDA to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain.

• #9 Alzheimer’s disease: Symptoms, stages, causes, and treatments

  https://www.medicalnewstoday.com/articles/159442

  The Food and Drug Administration (FDA) has approved the following cholinesterase inhibitors for Alzheimers disease: galantamine (Razadyne) to treat mild to moderate stages, rivastigmine (Exelon) to treat mild to moderate stages, donepezil (Aricept) to treat all stages. […] Another drug, memantine (Namenda), has FDA approval to treat moderate to severe Alzheimers disease. A combination of memantine and donepezil (Namzaric) is also available. […] There are now treatments that can slow the progression of Alzheimers disease. They include: lecanemab (Leqembi), which slowed progression by 25% in a phase 3 clinical trial, donanemab (Kisunla), which slowed cognitive decline by 32% in a review of previous studies, aducanemab (Aduhelm), which has only had modest effects on cognition and is still undergoing testing.

• #10 What’s Next for Alzheimer’s Disease Treatments: A 2024 Forecast

  https://www.brightfocus.org/resource/whats-next-for-alzheimers-disease-treatments-a-2024-forecast/

  Donanemab made headlines in 2023 as the amyloid-targeting drug with the highest slowing of cognitive decline at 35%. A separate analysis of those who received the drug early in their disease showed upwards of 60% slowing of cognitive decline, reinforcing the need for early intervention with Alzheimers and dementia treatments. Donanemab works by targeting and removing the hallmark amyloid plaques that appear in brains with Alzheimers disease. […] The drug manufacturer of the first disease-modifying oral medication for Alzheimers, ALZ-801, is expected to submit a new drug application to the FDA later this year. […] ALZ-801 targets an earlier form of amyloid that builds up in the brain and can negatively impact surrounding cells. Trials results reported thus far show less risk of a rare but serious side effect called amyloid-related imaging abnormalities, associated with current anti-amyloid medications.

• #11 FDA approves treatment for adults with Alzheimer’s disease | FDA

  https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease

  The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimers disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. […] Kisunla is administered as an intravenous infusion every four weeks. The recommended dosage is detailed in the prescribing information. […] The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimers disease. […] Patients treated with Kisunla demonstrated a statistically significant reduction in clinical decline on the Integrated Alzheimer’s Disease Rating Scale (iADRS) compared to placebo at Week 76 in the overall population (2.92, p0.0001), as well as on the iADRS component scales, the Alzheimers Disease Assessment Scale-Cognitive subscale (ADAS-Cog13) (-1.33, p=0.0006) and the Alzheimers Disease Cooperative Study instrumental Activities of Daily Living (ADCS-iADL) scale (1.70, p=0.0001). […] Patients treated with Kisunla also demonstrated a statistically significant reduction in clinical decline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo at Week 76 in the overall population (-0.70, p0.0001).

• #12 Alzheimer’s Disease: Diagnosis & Treatment | Massachusetts General Hospital

  https://www.massgeneral.org/neurology/treatments-and-services/alzheimers-disease/treatment

  For moderate to severe Alzheimers, memantine helps regulate glutamate, a brain chemical that, in excess, can damage brain cells. By controlling glutamate levels, memantine may help reduce symptoms and improve daily function in the later stages of Alzheimers. […] New immunotherapy treatments for Alzheimers disease (lecanemab and donanemab) have shown promise in slowing the diseases progression in its early stages. However, long-term results are still being studied. […] Two new immunotherapy drugs (lecanemab and donanemab) are the latest treatments for Alzheimer’s disease. The FDA approved lecanemab in January 2023 and donanemab in July 2024. Both drugs are considered disease-modifying treatments as they target the underlying physiopathology in the brain and have the potential to alter the course of the disease rather than manage symptoms.

• #13 Alzheimer’s disease – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453

  People taking lecanemab or donanemab may have swelling in the brain or may get small bleeds in the brain. Rarely, brain swelling can be serious enough to cause seizures and other symptoms. Also in rare instances, bleeding in the brain can cause death. The FDA recommends getting a brain MRI before starting treatment and regularly during treatment to monitor for symptoms of brain swelling or bleeding. […] Sometimes other medicines such as antidepressants may be prescribed to help manage the behavioral symptoms linked to Alzheimer’s disease. […] An important part of any treatment plan is to adapt to the needs of a person with Alzheimer’s disease. Create routine habits and cut down on tasks that require memory. These steps can make life much easier.

• #14

  https://www.nhs.uk/conditions/alzheimers-disease/treatment/

  There’s currently no cure for Alzheimer’s disease. But there is medicine available that can temporarily reduce the symptoms. […] A number of medicines may be prescribed for Alzheimer’s disease to help temporarily improve some symptoms. […] The main medicines are: […] Donepezil, galantamine and rivastigmine can be prescribed for people with early- to mid-stage Alzheimer’s disease. […] The latest guidelines recommend that these medicines should be continued in the later, severe, stages of the disease. […] Memantine is used for moderate or severe Alzheimer’s disease. It’s suitable for those who cannot take or are unable to tolerate AChE inhibitors. […] Antipsychotics are the only medicines licensed for people with moderate to severe Alzheimer’s disease where there’s a risk of harm to themselves or others.

• #15 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  Several prescription drugs are approved by the U.S. Food and Drug Administration (FDA) for Alzheimers disease to help either manage the symptoms of or to treat the disease. Most FDA-approved drugs work best for people in the early or middle stages of Alzheimers. There are currently no known interventions that will cure Alzheimers. […] Treating the symptoms of Alzheimers can help provide people with comfort, dignity, and independence for a longer period of time and also assist their caregivers. Galantamine, benzgalantamine, rivastigmine, and donepezil are cholinesterase inhibitors that are prescribed for mild to moderate Alzheimers symptoms. These drugs may help reduce or control some cognitive and behavioral symptoms. […] Lecanemab and donanemab are FDA-approved immunotherapy drugs for the treatment of early Alzheimers. These drugs target the protein beta-amyloid to help reduce amyloid plaques, one of the hallmark brain changes in Alzheimers.

• #16 Current and Future Treatments in Alzheimer Disease: An Update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7050025/

  The AChEIs donepezil, galantamine, rivastigmine, and the NMDA antagonist memantine are the only FDA-approved AD medications. […] Initiation of AChEI treatment as soon as possible after the diagnosis is preferred as patients who started the AChEI 6 months later showed more rapid cognitive decline than those who started the drug immediately. […] Memantine is a noncompetitive low-affinity NMDA-receptor open-channel blocker and affects glutamatergic transmission. […] Duration and persistence of monotherapy or combination treatment with higher doses in moderate or even in advanced dementia are associated with better global function and outcomes. […] Overall, there are 33 symptomatic agents in current trials: 19 agents aim to improve cognition and 14 target BPSD. […] Arduous research efforts persist to develop effective DMTs for AD, as well as symptomatic therapeutics. […] If all these research efforts come to fruition, an effective precision medicine context could be applied in every patient with AD in the near future: risk factor elimination, comorbid disease treatment, and personalized advice for lifestyle modification will be provided.

• #17 Alzheimer’s disease: Symptoms, stages, causes, and treatments

  https://www.medicalnewstoday.com/articles/159442

  The Food and Drug Administration (FDA) has approved the following cholinesterase inhibitors for Alzheimers disease: galantamine (Razadyne) to treat mild to moderate stages, rivastigmine (Exelon) to treat mild to moderate stages, donepezil (Aricept) to treat all stages. […] Another drug, memantine (Namenda), has FDA approval to treat moderate to severe Alzheimers disease. A combination of memantine and donepezil (Namzaric) is also available. […] There are now treatments that can slow the progression of Alzheimers disease. They include: lecanemab (Leqembi), which slowed progression by 25% in a phase 3 clinical trial, donanemab (Kisunla), which slowed cognitive decline by 32% in a review of previous studies, aducanemab (Aduhelm), which has only had modest effects on cognition and is still undergoing testing.

• #18

  https://www.nhs.uk/conditions/alzheimers-disease/treatment/

  There’s currently no cure for Alzheimer’s disease. But there is medicine available that can temporarily reduce the symptoms. […] A number of medicines may be prescribed for Alzheimer’s disease to help temporarily improve some symptoms. […] The main medicines are: […] Donepezil, galantamine and rivastigmine can be prescribed for people with early- to mid-stage Alzheimer’s disease. […] The latest guidelines recommend that these medicines should be continued in the later, severe, stages of the disease. […] Memantine is used for moderate or severe Alzheimer’s disease. It’s suitable for those who cannot take or are unable to tolerate AChE inhibitors. […] Antipsychotics are the only medicines licensed for people with moderate to severe Alzheimer’s disease where there’s a risk of harm to themselves or others.

• #19 Alzheimer’s disease: Symptoms, stages, causes, and treatments

  https://www.medicalnewstoday.com/articles/159442

  The Food and Drug Administration (FDA) has approved the following cholinesterase inhibitors for Alzheimers disease: galantamine (Razadyne) to treat mild to moderate stages, rivastigmine (Exelon) to treat mild to moderate stages, donepezil (Aricept) to treat all stages. […] Another drug, memantine (Namenda), has FDA approval to treat moderate to severe Alzheimers disease. A combination of memantine and donepezil (Namzaric) is also available. […] There are now treatments that can slow the progression of Alzheimers disease. They include: lecanemab (Leqembi), which slowed progression by 25% in a phase 3 clinical trial, donanemab (Kisunla), which slowed cognitive decline by 32% in a review of previous studies, aducanemab (Aduhelm), which has only had modest effects on cognition and is still undergoing testing.

• #20 How Alzheimer’s Disease Is Treated

  https://www.verywellhealth.com/alzheimers-treatment-4014202

  Cholinesterase inhibitors act by preventing the breakdown of acetylcholine in the brain. […] Researchers estimate that for about 50% of people with Alzheimer’s who take cholinesterase inhibitors, progression of Alzheimer’s symptoms is delayed for an average of six to 12 months. […] Namenda (memantine) is the only drug in this class, and it is approved for moderate to severe Alzheimer’s. Namenda appears to work by regulating levels of glutamate, an amino acid, in the brain. […] In 2021, the FDA approved the immunotherapy medication Aduhelm (aducanumab), and in 2023 approved Leqembi (lecanemab). Both medications were indicated to help treat cognitive symptoms by reducing amyloid plaques in the brain and slowing neurodegeneration and disease progression. […] Psychotropic medications are used at times to treat the behavioral, psychological, and emotional symptoms of Alzheimer’s diseasewhat is sometimes referred to as Behavioral and Psychological Symptoms of Dementia (BPSD).

• #21 Treatment of Alzheimer Disease | AAFP

  https://www.aafp.org/pubs/afp/issues/2011/0615/p1403.html

  A Cochrane review concluded that in patients with Alzheimer disease, treatment with donepezil, galantamine (Razadyne), or rivastigmine for six months to one year resulted in slightly improved cognitive function by an average of 2.7 points on the ADAS-cog. […] Improvements in behavior and activities of daily living also have been noted in patients treated with one of these three agents; however, none of the medications has a large treatment effect, and the clinical significance of these effects is questionable. […] Another systematic review concluded that, despite statistical significance, the improvement in patients with dementia taking acetylcholinesterase inhibitors was clinically marginal (0.1 to 5.3 points on the ADAS-cog). […] Additional trials are needed to determine the benefits of long-term therapy and whether these agents are effective in patients with moderate to severe Alzheimer disease.

• #22 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  A medication known as memantine, an N-methyl-D-aspartate (NMDA) antagonist, can be prescribed for moderate to severe Alzheimers. This drug is prescribed to decrease symptoms, which could enable some people to maintain certain daily functions a little longer than they would without the medication. […] The FDA has also approved donepezil, the rivastigmine patch, and a combination medication of memantine and donepezil for moderate to severe Alzheimers. […] Brexpiprazole is an atypical antipsychotic that has been approved to treat agitation associated with Alzheimers. […] The following list provides an overview of Alzheimers medications. […] FDA-approved medications to manage symptoms […] FDA-approved medications to treat Alzheimer’s […] Alzheimers researchers continue to explore a variety of innovative approaches to treat symptoms as well as underlying disease processes.

• #23 Current and Future Treatments in Alzheimer Disease: An Update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7050025/

  The AChEIs donepezil, galantamine, rivastigmine, and the NMDA antagonist memantine are the only FDA-approved AD medications. […] Initiation of AChEI treatment as soon as possible after the diagnosis is preferred as patients who started the AChEI 6 months later showed more rapid cognitive decline than those who started the drug immediately. […] Memantine is a noncompetitive low-affinity NMDA-receptor open-channel blocker and affects glutamatergic transmission. […] Duration and persistence of monotherapy or combination treatment with higher doses in moderate or even in advanced dementia are associated with better global function and outcomes. […] Overall, there are 33 symptomatic agents in current trials: 19 agents aim to improve cognition and 14 target BPSD. […] Arduous research efforts persist to develop effective DMTs for AD, as well as symptomatic therapeutics. […] If all these research efforts come to fruition, an effective precision medicine context could be applied in every patient with AD in the near future: risk factor elimination, comorbid disease treatment, and personalized advice for lifestyle modification will be provided.

• #24 Drugs for Alzheimer’s disease – Harvard Health

  https://www.health.harvard.edu/mind-and-mood/drugs-for-alzheimers-disease

  „It is prescribed to help slow down the progression of symptoms, which could enable some people to maintain some daily functions a little longer than they would without the medication,” says Dr. Budson. […] This new drug, approved by the FDA in January 2023, works differently from other Alzheimer’s drugs, as it helps to slow the progression of the disease. […] „The drug doesn’t stop new plaque from forming, but slows the speed at which it can accumulate,” says Dr. Budson. […] A study published Jan. 5, 2023, in The New England Journal of Medicine looked at 1,795 people who had amyloid plaques in their brains and mild memory problems. The researchers found that compared with people taking an inactive treatment, those who took lecanemab for 18 months had a slower rate of cognitive decline (as measured by cognitive tests) and less amyloid in their brains.

• #25 Alzheimer Disease Treatment & Management: Approach Considerations, Treatment of Mild to Moderate Disease, Treatment of Moderate to Severe Disease

  https://emedicine.medscape.com/article/1134817-treatment

  The partial N-methyl-D-aspartate (NMDA) antagonist memantine (Namenda, Namenda XR) is believed to work by improving the signal-to-noise ratio of glutamatergic transmission at the NMDA receptor. […] This agent is approved by the FDA for treating moderate and severe AD. […] Several studies have demonstrated that memantine can be safely used in combination with ChEIs. […] The combination of memantine with a ChEI has been shown to significantly delay institutionalization in AD patients. […] A variety of behavioral and pharmacologic interventions can alleviate clinical manifestations of AD, such as anxiety, agitation, depression, psychotic behavior, and sleep problems. […] At present, the FDA has not approved any psychotropic agent for the treatment of AD. […] Antidepressants have an important role in the treatment of mood disorders in patients with AD.

• #26 Alzheimer’s disease: Symptoms, stages, causes, and treatments

  https://www.medicalnewstoday.com/articles/159442

  The Food and Drug Administration (FDA) has approved the following cholinesterase inhibitors for Alzheimers disease: galantamine (Razadyne) to treat mild to moderate stages, rivastigmine (Exelon) to treat mild to moderate stages, donepezil (Aricept) to treat all stages. […] Another drug, memantine (Namenda), has FDA approval to treat moderate to severe Alzheimers disease. A combination of memantine and donepezil (Namzaric) is also available. […] There are now treatments that can slow the progression of Alzheimers disease. They include: lecanemab (Leqembi), which slowed progression by 25% in a phase 3 clinical trial, donanemab (Kisunla), which slowed cognitive decline by 32% in a review of previous studies, aducanemab (Aduhelm), which has only had modest effects on cognition and is still undergoing testing.

• #27 Medications for Memory, Cognition & Dementia-Related Behaviors | alz.org

  https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory

  Alzheimers affects more than just memory and thinking. A person’s quality of life may be impacted by a variety of behavioral and psychological symptoms that accompany dementia, such as sleep disturbances, agitation, hallucinations and delusions. […] The FDA has approved one drug to address symptoms of insomnia that has been tested in people living with dementia and one that treats agitation. […] Atypical antipsychotics are a group of antipsychotic drugs that target the serotonin and dopamine chemical pathways in the brain. […] Before beginning a new medication, make sure your physician and pharmacist are aware of all medications, dietary supplements or other products currently being taken (including over-the-counter and alternative preparations). […] Ultimately, the path to effective therapies is through clinical studies.

• #28 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  A medication known as memantine, an N-methyl-D-aspartate (NMDA) antagonist, can be prescribed for moderate to severe Alzheimers. This drug is prescribed to decrease symptoms, which could enable some people to maintain certain daily functions a little longer than they would without the medication. […] The FDA has also approved donepezil, the rivastigmine patch, and a combination medication of memantine and donepezil for moderate to severe Alzheimers. […] Brexpiprazole is an atypical antipsychotic that has been approved to treat agitation associated with Alzheimers. […] The following list provides an overview of Alzheimers medications. […] FDA-approved medications to manage symptoms […] FDA-approved medications to treat Alzheimer’s […] Alzheimers researchers continue to explore a variety of innovative approaches to treat symptoms as well as underlying disease processes.

• #29 Treatments for Behavior | Alzheimer’s Association

  https://www.alz.org/alzheimers-dementia/treatments/treatments-for-behavior

  Brexpiprazole (Rexulti) is the only atypical antipsychotic that is FDA-approved for agitation associated with dementia due to Alzheimer’s. […] The decision to use an antipsychotic drug needs to be considered with extreme caution. Research has shown that these drugs are associated with an increased risk of stroke and death in older adults with dementia.

• #30 Treatments for Behavior | Alzheimer’s Association

  https://www.alz.org/alzheimers-dementia/treatments/treatments-for-behavior

  Brexpiprazole (Rexulti) is the only atypical antipsychotic that is FDA-approved for agitation associated with dementia due to Alzheimer’s. […] The decision to use an antipsychotic drug needs to be considered with extreme caution. Research has shown that these drugs are associated with an increased risk of stroke and death in older adults with dementia.

• #31 Treatments for Alzheimer’s Disease

  https://www.everydayhealth.com/alzheimers-disease/guide/treatment/

  One drug, suvorexant (Belsomra), is approved for treatment of insomnia in Alzheimers. […] Many potential Alzheimers treatments are currently being investigated. […] Currently, there is no cure for Alzheimers disease, but new FDA-approved drugs can slow the disease, and various other drug treatments can help manage symptoms. Nondrug therapies are also important for maintaining quality of life.

• #32 New approaches to symptomatic treatments for Alzheimer’s disease | Molecular Neurodegeneration | Full Text

  https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-021-00424-9

  Development of new therapies for agitation is currently the most active area of drug development for neuropsychiatric symptoms in AD. […] There are no approved treatments for psychosis in any form of dementia. […] Apathy is among the most common manifestations of AD and other dementias. […] No treatment has been approved by the FDA for treatment of this neuropsychiatric syndrome. […] Sleep disorders are common in AD and affect the lives of the patient and the caregiver. […] Suvorexant, a dual orexin antagonist (DORA), was recently shown in a double blind, placebo-controlled phase 3 trial to reduce insomnia in AD. […] Additional agents currently under study for sleep disorders in AD include zopiclone and zolpidem. […] A major challenge for clinical trials of treatments for neuropsychiatric syndromes is the occurrence of robust placebo-group improvement.

• #33 Treatment of Alzheimer Disease | AAFP

  https://www.aafp.org/pubs/afp/issues/2011/0615/p1403.html

  It is reasonable to discontinue treatment if there is no improvement within six to eight weeks. […] Memantine prevents excessive glutamatergic activity. […] A meta-analysis concluded that memantine was ineffective for patients with mild Alzheimer disease, and the benefits for patients with moderate Alzheimer disease were inconsistent. […] Guidelines from the National Institute for Health and Clinical Excellence cite a study that found no improvement with memantine compared with placebo in patients who had moderate to severe Alzheimer disease. […] Older patients with dementia who are treated with atypical antipsychotics have a twofold higher mortality rate than those taking placebo. […] Using atypical antipsychotics to treat behavioral symptoms such as agitation in patients with Alzheimer disease generally should be avoided because of adverse effects, although these agents may be appropriate in some situations.

• #34 Dementia treatments | Alzheimer’s Society

  https://www.alzheimers.org.uk/about-dementia/treatments

  No current medications stop, slow down or reverse dementia, although some can temporarily help a person with their memory and thinking. […] These treatments are only effective for people with Alzheimers disease, dementia with Lewy bodies, Parkinsons disease dementia, and mixed dementia involving any of these types. […] Its not possible to know in advance if a persons symptoms will improve with treatment, as everyone responds differently. […] When a medication does help someone, symptoms tend to improve after a few weeks. […] It is common for people with dementia to develop changes in behaviour, such as agitation or aggression. Researchers have tried to see if dementia medications can help with these changes. Unfortunately, its currently unclear if they do. […] However, in most cases, with the right person-centred care and support, these changes will pass. Approaches that do not involve medications should always be tried first.

• #35 Treatment and support of Alzheimer’s disease | Alzheimer’s Society

  https://www.alzheimers.org.uk/about-dementia/types-dementia/treatment-support-alzheimers-disease

  There are many activities and therapies that can help a person with Alzheimers to maintain their abilities for as long as possible and to look after their physical and emotional wellbeing. […] Cognitive stimulation therapy (CST) This is a popular way to help keep someones mind active. It involves doing themed activity sessions over several weeks. […] Cognitive rehabilitation This is skills training that is tailored to a persons needs and abilities. It can enable the person to keep their thinking skills, meet their goals and cope better with the symptoms of dementia. […] Talking therapies, including counselling These can help someone come to terms with their diagnosis or discuss their feelings. […] Cognitive behavioural therapy (CBT) This may be offered if the person develops depression or anxiety. It is most useful in the early stages of Alzheimers disease. […] Some of these therapies may not be freely available in certain places. It may be necessary to search a wider area or pay privately to access them.

• #36 Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0615/p771.html

  A 2012 Cochrane meta-analysis of 15 randomized controlled trials concluded that cognitive stimulation programs are beneficial for maintenance of cognitive function and self-reported quality of life in patients with mild to moderate dementia from Alzheimer disease. […] Cholinesterase inhibitors, including donepezil (Aricept, 5 to 10 mg per day), galantamine (Razadyne, at least 16 mg per day), or rivastigmine (Exelon, 6 to 12 mg per day orally or 9.5 mg per day transdermally), should be considered for treatment of cognitive and functional decline in patients with mild to moderate Alzheimer disease. […] Memantine (Namenda, 20 mg per day) should be considered for treatment of cognitive and functional decline in patients with moderate to severe Alzheimer disease. […] The addition of vitamin E (2,000 IU per day) should be considered for treatment of mild to moderate Alzheimer disease in patients who are already receiving a cholinesterase inhibitor.

• #37

  https://www.nhs.uk/conditions/alzheimers-disease/treatment/

  Medicines for Alzheimer’s disease symptoms are only one part of the care for the person with dementia. […] Cognitive stimulation therapy (CST) involves taking part in group activities and exercises designed to improve memory and problem-solving skills. […] Cognitive rehabilitation works by getting you to use the parts of your brain that are working to help the parts that are not. […] Evidence shows they can improve mood and wellbeing.

• #38 Treatment and support of Alzheimer’s disease | Alzheimer’s Society

  https://www.alzheimers.org.uk/about-dementia/types-dementia/treatment-support-alzheimers-disease

  There are many activities and therapies that can help a person with Alzheimers to maintain their abilities for as long as possible and to look after their physical and emotional wellbeing. […] Cognitive stimulation therapy (CST) This is a popular way to help keep someones mind active. It involves doing themed activity sessions over several weeks. […] Cognitive rehabilitation This is skills training that is tailored to a persons needs and abilities. It can enable the person to keep their thinking skills, meet their goals and cope better with the symptoms of dementia. […] Talking therapies, including counselling These can help someone come to terms with their diagnosis or discuss their feelings. […] Cognitive behavioural therapy (CBT) This may be offered if the person develops depression or anxiety. It is most useful in the early stages of Alzheimers disease. […] Some of these therapies may not be freely available in certain places. It may be necessary to search a wider area or pay privately to access them.

• #39 Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0615/p771.html

  A structured physical exercise program should be recommended for patients with Alzheimer disease of any severity. […] Cognitive stimulation programs should be recommended for patients with mild to moderate cognitive impairment. […] Memantine has been studied in patients with Alzheimer disease, vascular dementia, and mixed dementia. RCTs comparing memantine with placebo generally demonstrate benefits in cognition, global status, and functional status in persons with moderate to severe dementia, although benefits are small and not consistently seen in those with less-severe disease. […] Given the clinical benefit, albeit small, and tolerability of memantine, it is a reasonable choice for use in the treatment of cognitive and functional symptoms in patients with moderate to severe Alzheimer disease.

• #40 Therapy for Alzheimer’s Disease: Types, Benefits, and More

  https://neuraleffects.com/blog/therapy-for-alzheimers-disease/

  For patients in the early stages of the disease, the best option includes some form of cognitive therapy, such as cognitive rehabilitation or cognitive stimulation therapy (which we use at Neural Effects and will describe later). […] Not surprisingly, the main benefit from cognitive therapies is a slower loss of cognitive function in patients who attend therapy compared to those who dont. […] Therapy also helps patients cope better with everyday activities and maintain their independence. […] As dementia progresses, patients also experience physical complications, such as stiff and/or weak muscles, fatigue, and loss of balance or coordination that can lead to falls. […] Physical activity also helps cognitive skills. […] The main benefit of these therapies is to help with symptoms of anxiety and depression.

• #41 What Are Therapy Options for Alzheimer’s Disease?Share to Facebookprint pageBookmark for latercaret iconFollow us on facebookFollow us on instagramFollow us on facebookFollow us on linkedincaret icon

  https://alzheimersdisease.net/physical-occupational-therapy

  At its most basic, occupational therapy (OT) helps people do things they want and need to do by adapting their everyday activities. For people with Alzheimer’s disease, this means adjusting their environment and figuring out how they can remain engaged, stay safe, and maintain quality of life. […] OT can be helpful at every stage of Alzheimer’s disease for both patients and caregivers, since the physical, mental, and emotional needs change as the disease progresses. […] Research shows that music and art therapy have positive effects on cognition and neuropsychiatric syndromes. These therapies may improve skills like executive functioning and global cognition. […] Research shows that exercise can help delay cognitive decline in those with Alzheimer’s disease. Exercise may also reduce the risk of developing Alzheimer’s disease. Exercise helps boost blood flow to the brain and can help reduce high blood pressure and high cholesterol, both of which are risk factors for dementia. […] If you or a loved one have Alzheimer’s disease and are interested in therapy options, talk to your care team. They can help you pick the right therapy options for your specific needs.

• #42 Non-drug interventions for Alzheimer’s disease

  https://www.informedhealth.org/non-drug-interventions-for-alzheimers-disease.html

  Research shows that social activities can improve the quality of life of people with Alzheimer’s and their family members. They can help prevent Alzheimers-related apathy. They can also reduce the amount of care needed. […] Studies suggest that cognitive interventions can temporarily improve mental performance and language abilities in mild and moderate Alzheimers disease. But they don’t improve a person’s ability to take care of themselves. It is not clear whether the therapies can improve mood or quality of life. […] Occupational therapy is an effective treatment method to train everyday abilities, such as getting dressed and housework. Occupational therapists help people with Alzheimer’s to keep on living as independently as possible. […] Psychological treatment may be considered if the disease causes severe mental health issues. It might aim to help people cope with the illness better and remain independent in everyday life for as long as possible. […] A large number of other non-drug interventions are available for the treatment of Alzheimers disease, such as aromatherapy. It is thought to help relax people who are restless or aggressive. Studies carried out so far have not been able to find any benefits to this treatment, though.

• #43 Treatment and support of Alzheimer’s disease | Alzheimer’s Society

  https://www.alzheimers.org.uk/about-dementia/types-dementia/treatment-support-alzheimers-disease

  There are many activities and therapies that can help a person with Alzheimers to maintain their abilities for as long as possible and to look after their physical and emotional wellbeing. […] Cognitive stimulation therapy (CST) This is a popular way to help keep someones mind active. It involves doing themed activity sessions over several weeks. […] Cognitive rehabilitation This is skills training that is tailored to a persons needs and abilities. It can enable the person to keep their thinking skills, meet their goals and cope better with the symptoms of dementia. […] Talking therapies, including counselling These can help someone come to terms with their diagnosis or discuss their feelings. […] Cognitive behavioural therapy (CBT) This may be offered if the person develops depression or anxiety. It is most useful in the early stages of Alzheimers disease. […] Some of these therapies may not be freely available in certain places. It may be necessary to search a wider area or pay privately to access them.

• #44 What Are Therapy Options for Alzheimer’s Disease?Share to Facebookprint pageBookmark for latercaret iconFollow us on facebookFollow us on instagramFollow us on facebookFollow us on linkedincaret icon

  https://alzheimersdisease.net/physical-occupational-therapy

  At its most basic, occupational therapy (OT) helps people do things they want and need to do by adapting their everyday activities. For people with Alzheimer’s disease, this means adjusting their environment and figuring out how they can remain engaged, stay safe, and maintain quality of life. […] OT can be helpful at every stage of Alzheimer’s disease for both patients and caregivers, since the physical, mental, and emotional needs change as the disease progresses. […] Research shows that music and art therapy have positive effects on cognition and neuropsychiatric syndromes. These therapies may improve skills like executive functioning and global cognition. […] Research shows that exercise can help delay cognitive decline in those with Alzheimer’s disease. Exercise may also reduce the risk of developing Alzheimer’s disease. Exercise helps boost blood flow to the brain and can help reduce high blood pressure and high cholesterol, both of which are risk factors for dementia. […] If you or a loved one have Alzheimer’s disease and are interested in therapy options, talk to your care team. They can help you pick the right therapy options for your specific needs.

• #45 Alzheimer’s Therapy: Medicines, Vitamin E, HRT, Sensory Therapy, and More

  https://www.webmd.com/alzheimers/alzheimers-disease-therapy-options

  There is no cure for Alzheimer’s. […] But if you or a loved one has Alzheimers, there are treatments that can make a difference. Some therapies ease the symptoms and help people do better for longer. […] Different types of drugs can treat memory loss, behavior changes, sleep problems, and other Alzheimers symptoms. […] The FDA has approved donanemab (Kisunla) and lecanemab-irmb (Leqembi) as two drug therapies that target and reduce these plaques. […] They cant reverse the damage already done but may slow progression. […] Many people have explored ways other than medication to treat Alzheimers disease or handle its symptoms. […] Music therapy can help someone with Alzheimers in numerous ways. […] Art therapy can help people with Alzheimers disease express themselves. […] Massage may help in two ways. It can ease agitation and improve sleep.

• #46 Alzheimer’s Treatment | Ohio State Medical Center

  https://wexnermedical.osu.edu/brain-spine-neuro/memory-disorders/alzheimers/treatment

  Well work to educate you and your caregiver on how to limit stressors and deal with conflict. Some ideas include creating routines to reduce confusion and breaking tasks into smaller steps to allow for focusing on success. […] Research on Alzheimer’s treatment: Learn how Deep Brain Stimulation may slow the progression of Alzheimer’s disease.

• #47 Alzheimer’s Disease > Fact Sheets > Yale Medicine

  https://www.yalemedicine.org/conditions/alzheimers-disease

  Environmental interventions. People with Alzheimers disease and their caregivers should modify their homes and activities to ensure safety and comfort. […] This starts with a detailed assessment of the cause of cognitive difficulties using multiple modern diagnostic technologies, and is followed by the deployment of diverse pharmacological, behavioral, and lifestyle interventions to limit symptoms and their impact on patients and families.

• #48 Alzheimer’s Treatment Options: Early & Non-Drug Interventions

  https://neuraleffects.com/blog/intervention-for-alzheimers-disease/

  At this stage, the main aim of late interventions is to support the patient and keep them comfortable and pain-free. […] Doctors may change to a glutamate regulator called memantine (Namenda) when this happens. […] Patients with late Alzheimers can still engage in many of the therapies described earlier, but activities need to be adjusted to the patients abilities. […] One specific type of therapy that may help patients with late Alzheimers is called multisensory stimulation therapy. […] Patients with late Alzheimers may also enjoy doll therapy. […] Finally, aromatherapy is quickly growing in popularity among patients with dementia. […] During the later stages, interventions at home should focus on preserving the aging parents quality of life and dignity. […] Establishing a daily routine can help patients stay focused and oriented.

• #49 Alzheimer’s Treatment | Ohio State Medical Center

  https://wexnermedical.osu.edu/brain-spine-neuro/memory-disorders/alzheimers/treatment

  Also, our Alzheimers doctors successfully treat many of the diseases behavioral symptoms, including depression, anxiety, restless behaviors, psychosis, paranoia, hallucinations, mood changes, sleep disorders and appetite disturbances. This can improve quality of life for both you and your caregivers. […] Some symptoms of Alzheimers disease, such as restlessness, agitation, depression and mood changes, can be treated by using environmental and behavioral techniques, in addition to medications. […] Our occupational therapists offer tips to modifying home environments to make them safer and less stressful for those with dementia. […] Our highly trained social workers can link you and your caregiver to community resources and options with assisted living, nursing homes and daycare facilities.

• #50 Alzheimer’s treatments: What’s on the horizon?

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780

  Despite many promising leads, new treatments for Alzheimer’s are slow to emerge. […] Current Alzheimer’s treatments temporarily improve symptoms of memory loss and problems with thinking and reasoning. […] These Alzheimer’s treatments boost the performance of chemicals in the brain that carry information from one brain cell to another. They include cholinesterase inhibitors and the medicine memantine (Namenda). However, these treatments don’t stop the underlying decline and death of brain cells. As more cells die, Alzheimer’s disease continues to progress. […] Experts are cautious but hopeful about developing treatments that can stop or delay the progression of Alzheimer’s. […] Future Alzheimer’s treatments may include a combination of medicines. This is similar to treatments for many cancers or HIV/AIDS that include more than one medicine.

• #51 What’s Next for Alzheimer’s Disease Treatments: A 2024 Forecast

  https://www.brightfocus.org/resource/whats-next-for-alzheimers-disease-treatments-a-2024-forecast/

  From upcoming drug approval decisions to late-stage clinical trial readouts this year promises many developments for Alzheimers and dementia treatments coming down the pipeline. In 2024, there are 171 ongoing studies and 134 drugs being tested in clinical trials. […] Over half (77%) of the new treatments are touted as potentially disease-modifying, meaning they target known pathological changes in Alzheimers disease to slow cognitive decline. This strategy is intended to give people in the early stages of Alzheimers disease a little more time before they start to lose their cognitive abilities and begin experiencing symptoms like memory loss. […] There are limited treatment options for Alzheimers disease currently available, and only a small portion are considered disease-modifying. Those drugs have shown modest results for slowing progression, leaving room for improvement and innovation in upcoming therapies. The next generation of treatments are making their way through clinical trials and roughly 15% of new drugs are in later-stage studies (Phase 3).

• #52 Alzheimer’s treatments: What’s on the horizon?

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780

  A vital brain cell transport system collapses when a protein called tau twists into tiny fibers. […] Researchers are looking at a way to prevent tau from forming tangles. […] The medicine sargramostim (Leukine) is currently in research. The medicine may stimulate the immune system to protect the brain from harmful proteins. […] Studies are looking into how insulin may affect the brain and brain cell function. […] Researchers are studying how insulin changes in the brain may be related to Alzheimer’s. […] Research suggests that lifestyle choices with known heart benefits may help prevent Alzheimer’s disease or delay its onset. […] Studies during the 1990s suggested that taking hormone replacement therapy during perimenopause and menopause lowered the risk of Alzheimer’s disease.

• #53 The future of Alzheimer’s treatment

  https://www.nature.com/articles/d41586-025-01102-2

  Although they get the lions share of attention, amyloid- plaques are not the only targets for Alzheimers therapies that are under development. […] Various potential anti-tau therapies are in early-stage trials, including antibodies, a vaccine, small molecules and DNA-based techniques. […] The idea is that this disposal failure causes waste including amyloid- to accumulate inside cells, ultimately killing them and spilling ready-made plaques into the brain. […] If Nixon is right, then, just as vacuuming up wood dust from the floor wont solve the problem of termites in your wall, clearing amyloid- plaques will never halt the disease, because it doesnt address the underlying problem. […] Today’s plaque-clearing anti-amyloid drugs are a valuable and significant step forward. But as understanding of the disease grows, so does the feeling that stopping Alzheimers might require treatments that do more than these antibodies can.

• #54 What’s Next for Alzheimer’s Disease Treatments: A 2024 Forecast

  https://www.brightfocus.org/resource/whats-next-for-alzheimers-disease-treatments-a-2024-forecast/

  Donanemab made headlines in 2023 as the amyloid-targeting drug with the highest slowing of cognitive decline at 35%. A separate analysis of those who received the drug early in their disease showed upwards of 60% slowing of cognitive decline, reinforcing the need for early intervention with Alzheimers and dementia treatments. Donanemab works by targeting and removing the hallmark amyloid plaques that appear in brains with Alzheimers disease. […] The drug manufacturer of the first disease-modifying oral medication for Alzheimers, ALZ-801, is expected to submit a new drug application to the FDA later this year. […] ALZ-801 targets an earlier form of amyloid that builds up in the brain and can negatively impact surrounding cells. Trials results reported thus far show less risk of a rare but serious side effect called amyloid-related imaging abnormalities, associated with current anti-amyloid medications.

• #55 Alzheimer’s treatments: What’s on the horizon?

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780

  Some of the new Alzheimer’s treatments target clumps of the protein beta-amyloid, known as plaques, in the brain. […] Medicines known as monoclonal antibodies may prevent beta-amyloid from clumping into plaques. They also may remove beta-amyloid plaques that have formed. […] The U.S. Food and Drug Administration (FDA) has approved lecanemab (Leqembi) and donanemab (Kisunla) for people with mild Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease. […] Clinical trials found that the medicines slowed declines in thinking and functioning in people with early Alzheimer’s disease. […] A medicine initially developed as a possible cancer treatment saracatinib is now being tested in Alzheimer’s disease. […] Human trials for saracatinib as a possible Alzheimer’s treatment are now underway.

• #56 Alzheimer’s treatments: What’s on the horizon?

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780

  A vital brain cell transport system collapses when a protein called tau twists into tiny fibers. […] Researchers are looking at a way to prevent tau from forming tangles. […] The medicine sargramostim (Leukine) is currently in research. The medicine may stimulate the immune system to protect the brain from harmful proteins. […] Studies are looking into how insulin may affect the brain and brain cell function. […] Researchers are studying how insulin changes in the brain may be related to Alzheimer’s. […] Research suggests that lifestyle choices with known heart benefits may help prevent Alzheimer’s disease or delay its onset. […] Studies during the 1990s suggested that taking hormone replacement therapy during perimenopause and menopause lowered the risk of Alzheimer’s disease.

• #57 Stem Cell Therapy for Alzheimer’s: Findings and Treatment (2025)

  https://www.dvcstem.com/post/stem-cell-therapy-for-alzheimers

  Studies have shown that MSCs can help to reduce the buildup of A plaques in the brain and improve cognitive function in animal models of Alzheimer’s disease. […] While more research is needed to validate the use of MSCs as a treatment for Alzheimer’s disease, early studies have shown promising results. […] Stem cell therapy has emerged as a promising treatment for Alzheimer’s disease, with numerous studies suggesting that it can improve cognitive function and reduce the symptoms of the disease. […] Stem cell therapy has the potential to repair damaged brain tissue and reduce inflammation, which are two of the significant contributors to the development and progression of Alzheimer’s disease. […] Stem cell therapy has shown promise in treating Alzheimer’s disease by addressing the underlying causes of the disease, such as reducing the number of amyloid deposits and beta-amyloid plaques in the brain, which is thought to play a role in the cognitive decline associated with Alzheimer’s.

• #58 Stem Cell Therapy for Alzheimer’s: Findings and Treatment (2025)

  https://www.dvcstem.com/post/stem-cell-therapy-for-alzheimers

  Despite the potential benefits, stem cell therapy for Alzheimer’s is still considered experimental, and more research is needed to validate its use as a treatment. […] However, stem cell therapy shows promise as a potential treatment for Alzheimer’s, with mesenchymal stem cells being a current research focus.

• #59 Alzheimer’s Disease: Diagnosis & Treatment | NewYork-Presbyterian

  https://www.nyp.org/neuro/alzheimers-disease/treatment

  Treatment for Alzheimers disease can include medications that may ease symptoms such as memory loss and other forms of cognitive decline. […] Cholinesterase inhibitors are often prescribed to help decrease the breakdown of acetylcholine, a neurotransmitter that is diminished in the brains of individuals with Alzheimers disease. […] Memantine (Namenda) is another medication that can be prescribed to slow the progression of symptoms in individuals with Alzheimers disease. […] Lecanemab-irmb (Leqembi TM) is FDA-approved for slowing the progression of Alzheimers disease. […] Certain lifestyle choices may contribute to the preservation of overall cognitive health. […] Encouraging continual social interactions and mental exercise can be beneficial. […] Clinical studies are currently being conducted by NewYork-Presbyterian Hospital to understand better what causes Alzheimers disease and discover preventative measures and possible cures. […] Medications are available which may prevent Alzheimer’s from progressing, but they will not cure the disease or reverse the damage done.

• #60 Alzheimer’s treatments: What’s on the horizon?

  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780

  Despite many promising leads, new treatments for Alzheimer’s are slow to emerge. […] Current Alzheimer’s treatments temporarily improve symptoms of memory loss and problems with thinking and reasoning. […] These Alzheimer’s treatments boost the performance of chemicals in the brain that carry information from one brain cell to another. They include cholinesterase inhibitors and the medicine memantine (Namenda). However, these treatments don’t stop the underlying decline and death of brain cells. As more cells die, Alzheimer’s disease continues to progress. […] Experts are cautious but hopeful about developing treatments that can stop or delay the progression of Alzheimer’s. […] Future Alzheimer’s treatments may include a combination of medicines. This is similar to treatments for many cancers or HIV/AIDS that include more than one medicine.

• #61 Current and Future Treatments in Alzheimer Disease: An Update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7050025/

  In this review, we discuss potential disease-modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD. […] All of the already established treatments that are used today try to counterbalance the neurotransmitter imbalance of the disease. The acetylocholinesterase inhibitors (AChEIs) which are approved for the treatment of AD are donepezil, galantamine, and rivastigmine. […] A further therapeutic agent approved for moderate to severe AD is the low-to-moderate affinity, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine. […] In clinical trials, both A and tau are prime targets for disease-modifying treatments (DMTs) in AD. […] A multifactorial tailored management of AD is attempted nowadays based in the following components: Open physician, caregiver, and patient communication: a sincere and successful conveying of information and feelings between them will offer opportune identifying of symptoms, exact evaluation and diagnosis, and suitable guidance.

• #62 Current and Future Treatments in Alzheimer Disease: An Update

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7050025/

  In this review, we discuss potential disease-modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD. […] All of the already established treatments that are used today try to counterbalance the neurotransmitter imbalance of the disease. The acetylocholinesterase inhibitors (AChEIs) which are approved for the treatment of AD are donepezil, galantamine, and rivastigmine. […] A further therapeutic agent approved for moderate to severe AD is the low-to-moderate affinity, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine. […] In clinical trials, both A and tau are prime targets for disease-modifying treatments (DMTs) in AD. […] A multifactorial tailored management of AD is attempted nowadays based in the following components: Open physician, caregiver, and patient communication: a sincere and successful conveying of information and feelings between them will offer opportune identifying of symptoms, exact evaluation and diagnosis, and suitable guidance.

• #63 Anti-amyloid drug shows signs of preventing Alzheimer’s dementia – WashU Medicine

  https://medicine.washu.edu/news/anti-amyloid-drug-shows-signs-of-preventing-alzheimers-dementia/

  The findings suggest for the first time in a clinical trial that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimers dementia. […] In order to give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all. What we do know is that its possible at least to delay the onset of the symptoms of Alzheimers disease and give people more years of healthy life. […] The findings provide new evidence to support the so-called amyloid hypothesis of Alzheimers disease, which posits that the first step on the road to dementia is the build-up of amyloid plaques in the brain, and that removing such plaques or blocking their formation can stop symptoms from arising.

• #64 Lecanemab, the New Alzheimer’s Treatment: 3 Things To Know > News > Yale Medicine

  https://www.yalemedicine.org/news/lecanemab-leqembi-new-alzheimers-drug

  The antibody treatment selectively targets the forms of amyloid protein that are thought to be the most toxic to brain cells, says Dr. van Dyck. […] Study participants who received the treatment had a significant reduction in amyloid burden in imaging tests, usually reaching normal levels by the end of the trial. […] Lecanemab is already being tested in the global AHEAD study for individuals who are still cognitively normal but at high risk of symptoms due to elevated levels of brain amyloid. […] So, for drugs in this class, I think lecanemab has a favorable safety profile, he says. […] Eisai set the price for Leqembi at $26,500 per year, and it has reportedly been largely unavailable while FDA full approval was pending.

• #65 Alzheimer’s Disease  – Focused Ultrasound Foundation

  https://www.fusfoundation.org/diseases-and-conditions/alzheimers-disease/

  Focused ultrasound for this condition is being researched in clinical trials. […] Focused ultrasound is a noninvasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with Alzheimer’s disease. This novel technology focuses beams of ultrasonic energy precisely and accurately on targets deep in the brain without damaging the surrounding normal tissue. […] Promising preclinical studies continue to demonstrate the potential of focused ultrasound to enhance the delivery of therapeutic drugs or antibodies to the brain. […] A clinical trial in Utah is treating patients with Alzheimer’s Disease with low intensity focused ultrasound. […] A clinical trial in West Virginia is combining opening of the BBB with Aducanumab in patients with early cognitive disability or Alzheimer’s disease.

• #66 Treatments & Research | Alzheimer’s Association

  https://www.alz.org/help-support/i-have-alz/treatments-research

  The more you know about Alzheimer’s medications, the better prepared you will be to discuss them with your physician and make informed choices about your treatment plan. Although current medications cannot cure Alzheimers, some drugs change disease progression, with benefits to cognition and function. Other medicines may help lessen symptoms, such as memory loss and confusion, for a limited time. […] The U.S. Food and Drug Administration (FDA) has approved medications that fall into two categories: drugs that change disease progression in people living with Alzheimers, and drugs that may temporarily mitigate some symptoms of the disease. […] Drugs in this category slow disease progression by going after the underlying biology of the disease process. They aim to slow the decline of memory and thinking, as well as function, in people living with Alzheimer’s disease.

• #67 Navigating Treatment Options | alz.org

  https://www.alz.org/alzheimers-dementia/treatments/navigating-treatment-options

  Donanemab (Kisunla) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every four weeks. It has received traditional approval from the FDA to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain. The positive data from the clinical studies showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (either mild cognitive impairment or mild dementia). […] Lecanemab (Leqembi) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every two weeks. It has received traditional approval from the FDA to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain.

• #68 Navigating Treatment Options | alz.org

  https://www.alz.org/alzheimers-dementia/treatments/navigating-treatment-options

  Donanemab (Kisunla) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every four weeks. It has received traditional approval from the FDA to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain. The positive data from the clinical studies showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (either mild cognitive impairment or mild dementia). […] Lecanemab (Leqembi) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every two weeks. It has received traditional approval from the FDA to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain.

• #69 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  Several prescription drugs are approved by the U.S. Food and Drug Administration (FDA) for Alzheimers disease to help either manage the symptoms of or to treat the disease. Most FDA-approved drugs work best for people in the early or middle stages of Alzheimers. There are currently no known interventions that will cure Alzheimers. […] Treating the symptoms of Alzheimers can help provide people with comfort, dignity, and independence for a longer period of time and also assist their caregivers. Galantamine, benzgalantamine, rivastigmine, and donepezil are cholinesterase inhibitors that are prescribed for mild to moderate Alzheimers symptoms. These drugs may help reduce or control some cognitive and behavioral symptoms. […] Lecanemab and donanemab are FDA-approved immunotherapy drugs for the treatment of early Alzheimers. These drugs target the protein beta-amyloid to help reduce amyloid plaques, one of the hallmark brain changes in Alzheimers.

• #70 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  A medication known as memantine, an N-methyl-D-aspartate (NMDA) antagonist, can be prescribed for moderate to severe Alzheimers. This drug is prescribed to decrease symptoms, which could enable some people to maintain certain daily functions a little longer than they would without the medication. […] The FDA has also approved donepezil, the rivastigmine patch, and a combination medication of memantine and donepezil for moderate to severe Alzheimers. […] Brexpiprazole is an atypical antipsychotic that has been approved to treat agitation associated with Alzheimers. […] The following list provides an overview of Alzheimers medications. […] FDA-approved medications to manage symptoms […] FDA-approved medications to treat Alzheimer’s […] Alzheimers researchers continue to explore a variety of innovative approaches to treat symptoms as well as underlying disease processes.

• #71 How Is Alzheimer’s Disease Treated? | National Institute on Aging

  https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated

  A medication known as memantine, an N-methyl-D-aspartate (NMDA) antagonist, can be prescribed for moderate to severe Alzheimers. This drug is prescribed to decrease symptoms, which could enable some people to maintain certain daily functions a little longer than they would without the medication. […] The FDA has also approved donepezil, the rivastigmine patch, and a combination medication of memantine and donepezil for moderate to severe Alzheimers. […] Brexpiprazole is an atypical antipsychotic that has been approved to treat agitation associated with Alzheimers. […] The following list provides an overview of Alzheimers medications. […] FDA-approved medications to manage symptoms […] FDA-approved medications to treat Alzheimer’s […] Alzheimers researchers continue to explore a variety of innovative approaches to treat symptoms as well as underlying disease processes.

• #72 Treatments for Alzheimer’s Disease

  https://www.everydayhealth.com/alzheimers-disease/guide/treatment/

  One drug, suvorexant (Belsomra), is approved for treatment of insomnia in Alzheimers. […] Many potential Alzheimers treatments are currently being investigated. […] Currently, there is no cure for Alzheimers disease, but new FDA-approved drugs can slow the disease, and various other drug treatments can help manage symptoms. Nondrug therapies are also important for maintaining quality of life.

• #73 Treatment and support of Alzheimer’s disease | Alzheimer’s Society

  https://www.alzheimers.org.uk/about-dementia/types-dementia/treatment-support-alzheimers-disease

  There are many activities and therapies that can help a person with Alzheimers to maintain their abilities for as long as possible and to look after their physical and emotional wellbeing. […] Cognitive stimulation therapy (CST) This is a popular way to help keep someones mind active. It involves doing themed activity sessions over several weeks. […] Cognitive rehabilitation This is skills training that is tailored to a persons needs and abilities. It can enable the person to keep their thinking skills, meet their goals and cope better with the symptoms of dementia. […] Talking therapies, including counselling These can help someone come to terms with their diagnosis or discuss their feelings. […] Cognitive behavioural therapy (CBT) This may be offered if the person develops depression or anxiety. It is most useful in the early stages of Alzheimers disease. […] Some of these therapies may not be freely available in certain places. It may be necessary to search a wider area or pay privately to access them.

• #74 Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms | AAFP

  https://www.aafp.org/pubs/afp/issues/2017/0615/p771.html

  A structured physical exercise program should be recommended for patients with Alzheimer disease of any severity. […] Cognitive stimulation programs should be recommended for patients with mild to moderate cognitive impairment. […] Memantine has been studied in patients with Alzheimer disease, vascular dementia, and mixed dementia. RCTs comparing memantine with placebo generally demonstrate benefits in cognition, global status, and functional status in persons with moderate to severe dementia, although benefits are small and not consistently seen in those with less-severe disease. […] Given the clinical benefit, albeit small, and tolerability of memantine, it is a reasonable choice for use in the treatment of cognitive and functional symptoms in patients with moderate to severe Alzheimer disease.

• #75 Alzheimer’s Treatment | Ohio State Medical Center

  https://wexnermedical.osu.edu/brain-spine-neuro/memory-disorders/alzheimers/treatment

  Well work to educate you and your caregiver on how to limit stressors and deal with conflict. Some ideas include creating routines to reduce confusion and breaking tasks into smaller steps to allow for focusing on success. […] Research on Alzheimer’s treatment: Learn how Deep Brain Stimulation may slow the progression of Alzheimer’s disease.

• #76 Alzheimer’s Disease > Fact Sheets > Yale Medicine

  https://www.yalemedicine.org/conditions/alzheimers-disease

  Environmental interventions. People with Alzheimers disease and their caregivers should modify their homes and activities to ensure safety and comfort. […] This starts with a detailed assessment of the cause of cognitive difficulties using multiple modern diagnostic technologies, and is followed by the deployment of diverse pharmacological, behavioral, and lifestyle interventions to limit symptoms and their impact on patients and families.

• #77 Navigating Treatment Options | alz.org

  https://www.alz.org/alzheimers-dementia/treatments/navigating-treatment-options

  It is important to seek a diagnosis as early as possible. The earlier you are diagnosed, the more treatment options will be available to you. Some medications are only effective in the early stages of the disease. […] Your doctor may have a conversation with you about how well some of the Alzheimer’s treatments work. They may discuss if the potential benefits outweigh the risk of any side effects. […] Because drugs that treat the progression of the disease are newer, coverage is an evolving issue. You should talk to your doctor about coverage and if they can help with appeals. The Centers for Medicare Medicaid Services (CMS) announced they will cover lecanemab (Leqembi) as long as an individual’s physician enrolls them in a CMS-run registry.

• #78 Alzheimer’s Disease Treatment: Medications & Lifestyle Changes | SELF

  https://www.self.com/story/alzheimers-disease-treatment

  Medication wont turn back the clock, but it can improve your quality of life. […] Alzheimers disease doesnt have a cure, meaning no treatment can reverse the damage thats already occurred in the brain. […] There are ways to manage symptoms so people with Alzheimers can still have fulfilling lives and caregivers can continue to have meaningful experiences with their loved ones. […] Several medications may ease Alzheimers symptoms or temporarily slow the diseases progression. […] The FDA-approved therapies for Alzheimers fall into two camps: medications that may temporarily improve symptoms (like impaired memory and thinking) and drugs that aim to slow the rate of cognitive decline. […] To recommend the right drug for you or your loved one, a neurologist will determine whether the disease is in a mild, moderate, or severe stage and evaluate each treatments potential efficacy and safety risks based on symptoms and medical history.

• #79 Alzheimer’s Disease: Symptoms, Treatment, and Diagnosis

  https://www.healthline.com/health/alzheimers-disease

  Theres no cure for Alzheimers, but there are treatments that can slow the progression of the disease. […] Theres no cure for Alzheimers yet, but treatment can help slow the progression of the disease and may improve quality of life. […] However, your doctor can recommend medications and other treatments to help ease your symptoms and delay the progression of the disease for as long as possible. […] Although the care needs of someone with Alzheimers will increase over time, the exact symptoms will be different from person to person. […] Along with your doctor, a team of healthcare professionals can help you maintain your quality of life at all stages of Alzheimers disease. […] In addition to lifestyle changes, there are several alternative and complementary therapies you can ask your doctor about. […] By the time Alzheimers is diagnosed, the progression of the disease cant be stopped. But treatment can help delay symptoms and improve your quality of life.

• #80 Alzheimer’s Disease Treatment: Medications & Lifestyle Changes | SELF

  https://www.self.com/story/alzheimers-disease-treatment

  Medication is just one piece of the puzzle. […] While these strategies wont turn back the clock in the brain of someone with Alzheimers, they make a difference by tamping down stress, a common trigger that can exacerbate symptoms of the disease. […] Many experts in the field are hopeful that lecanemab and donanemab are just the beginning of an era of breakthroughs in Alzheimers therapy. […] Scientists are also studying other aspects of the Alzheimers process to develop medications that could, say, repair dementia-related brain damage or protect cells from the molecular onslaught of the disease.

Zobacz więcej